This post was originally published on this site Women with HER2-positive breast cancer that has spread to distant organs live longer if they have surgery to remove their primary tumor, according to research presented at the recent American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia. The findings were featured on the…
This post was originally published on this site Adding ADXS-PSA, an investigational cancer vaccine, to Keytruda (pembrolizumab) is showing positive signs of safety and efficacy in patients with metastatic, castration-resistant prostate cancer (mCRPC), and appears to prolong survival compared with standard-of-care therapy, early results from an ongoing Phase 1/2 trial show. The results were announced…
This post was originally published on this site A Phase 1 clinical trial is recruiting relapsed or refractory non-Hodgkin’s lymphoma patients to determine the safest and most effective dose of the oral therapy CA-4948. The trial is now treating patients in its fifth dosing group, Curis announced. CA-4948, developed by Curis in collaboration with Aurigene, is a small molecule that works by…
This post was originally published on this site A new web-based tool, called PREDICT Prostate, incorporates patients’ clinical and demographic data to provide a personalized prognosis to men with prostate cancer, helping them choose between radical treatment or watchful waiting. The online tool was launched the same day the results of the study, “Individual prognosis…
This post was originally published on this site With the aim of advancing personalized therapy, a pilot study will investigate a possible correlation between gut microbiome and ovarian cancer. The investigation is the initial development of a new partnership between Viome, whose proprietary gut microbiome test is used to personalize diet and nutrition recommendations, and…
This post was originally published on this site Ygalo (melflufen), a novel compound under investigation for relapsed and refractory multiple myeloma, was well-tolerated and demonstrated promising signs of high efficacy in two global clinical trials conducted by Oncopeptides. The data was presented April 1–2 at this year’s American Association for Cancer Research Annual Meeting, held in…
This post was originally published on this site The American Lung Association and Foundation for Sarcoidosis Research are working together during April’s Sarcoidosis Awareness Month to offer U.S. sarcoidosis patients and caregivers additional support, making available in-person support groups and online tutorials by specialists. As part of the activities of Sarcoidosis Awareness Month, the associations…
This post was originally published on this site The Phase 2 clinical trial assessing Moleculin Biotech‘s STAT3 inhibitor, WP1220, for the topical treatment of cutaneous T-cell lymphoma (CTCL) lesions has enrolled the first two participants. The trial, to assess WP1220‘s safety and efficacy, has been reviewed and approved by regulatory authorities in Poland, where the study will be conducted.…
This post was originally published on this site A Phase 1/2 clinical trial testing a triple immunotherapy combination for newly diagnosed glioblastoma has completed patient enrollment three months ahead of schedule. Inovio Pharmaceuticals, the company leading the trial, announced the trial (NCT03491683) has enrolled the planned 52 participants at centers across the U.S. The trial is…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has expanded the use of Ibrance (palbociclib) capsules in combination with an aromatase inhibitor or Faslodex (fulvestrant) to men with a subset of advanced breast cancer. The approval of Pfizer’s supplemental New Drug Application (sNDA) makes such first-line treatment available for…
